

August 11, 2026

To
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot C-1, Block- G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

NSE Scrip: VILINBIO

Sub: Receipt of Observation Letter from the National Stock Exchange of India Limited in relation to the Scheme of Amalgamation of M/s Chemgenix Laboratories Private Limited ("Transferor Company") into M/s Vilin Bio Med Limited ("Transferee Company")

Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("Listing Regulations")

Dear Sir / Madam,

This is in furtherance to our intimation dated February 16, 2026 w.r.t. the proposed Scheme of Amalgamation between M/s Chemgenix Laboratories Private Limited ("Transferor Company") into M/s Vilin Bio Med Limited ("Transferee Company") and their respective Shareholders and Creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 read with the Rules made thereunder ("Scheme").

In this regard, we would like to inform you that the Company has received Observation Letter with 'No Objection' from the National Stock Exchange of India Limited ("NSE") dated August 10, 2026.

The Scheme remains subject to various Statutory and Regulatory approvals and of the respective Shareholders and Creditors of the Companies involved in the Scheme, as and when required.

The Observation Letter received from the NSE is also made available on the website of the Company at www.vilinbio.com.

Kindly take the same on record.

For Vilin Bio Med Limited

Madhusudhan Yadamakanti Reddy
Managing Director
DIN: 02874260